Milestone Pharmaceuticals (MIST)
(Real Time Quote from BATS)
$1.48 USD
+0.05 (3.50%)
Updated Aug 4, 2025 10:28 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MIST 1.48 +0.05(3.50%)
Will MIST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
Other News for MIST
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
12 Health Care Stocks Moving In Friday's Intraday Session
Milestone Pharmaceuticals (MIST) Shares Plummet After $52.5 Million Offering Announcement
Milestone Pharmaceuticals plunges after pricing $52.5M offering
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings